Illustrative flow cytometry plots (Figure 1D–F) show that CD3+CD20+ T cells as well as CD20+CD19+ B cells were rapidly and efficiently depleted from peripheral blood of MS patients after one dose of ocrelizumab. The gene discussed is CD19; the disease is myeloid sarcoma.